Volume 60, Issue 2, Pages (August 2011)

Slides:



Advertisements
Similar presentations
Volume 50, Issue 1, Pages (July 2006)
Advertisements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 58, Issue 2, Pages (August 2010)
Volume 44, Issue 6, Pages (December 2003)
Volume 66, Issue 6, Pages (December 2014)
Global Trends in Testicular Cancer Incidence and Mortality
Volume 61, Issue 5, Pages (May 2012)
Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine  Carolyn D. Hurst, Fiona M. Platt, Margaret.
Volume 70, Issue 2, Pages (August 2016)
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Volume 51, Issue 5, Pages (May 2007)
Prostate Cancer Epidemic in Sight?
Volume 52, Issue 4, Pages (October 2007)
Volume 63, Issue 4, Pages (April 2013)
Volume 59, Issue 2, Pages (February 2011)
Volume 63, Issue 1, Pages (January 2013)
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Volume 65, Issue 5, Pages (May 2014)
Volume 66, Issue 2, Pages (August 2014)
The Global Risk of Bladder Cancer: Let's Just Do Something About It!
Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer  Sam Ladjevardi, Gabriel Sandblom,
Volume 74, Issue 1, Pages (July 2018)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey  John B. McKinlay, Carol L. Link  European.
Volume 71, Issue 1, Pages 1-3 (January 2017)
Volume 61, Issue 5, Pages (May 2012)
Volume 61, Issue 4, Pages (April 2012)
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma  Viktor Grünwald, Xun Lin, Daniel Kalanovic,
Volume 69, Issue 3, Pages (March 2016)
Volume 64, Issue 3, Pages (September 2013)
Prostate Cancer Epidemic in Sight?
Volume 61, Issue 6, Pages (June 2012)
Volume 53, Issue 2, Pages (February 2008)
Volume 74, Issue 3, Pages (September 2018)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 53, Issue 6, Pages (June 2008)
Volume 66, Issue 6, Pages (December 2014)
Volume 66, Issue 6, Pages (December 2014)
Volume 66, Issue 2, Pages (August 2014)
Volume 63, Issue 3, Pages (March 2013)
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 74, Issue 2, Pages (August 2018)
Radical Perineal Prostatectomy and Simultaneous Extended Pelvic Lymph Node Dissection via the Same Incision  Hansjörg Keller, Joachim Lehmann, Jörn Beier 
The Economic Costs of Overactive Bladder in Germany
Volume 69, Issue 6, Pages (June 2016)
Volume 70, Issue 2, Pages (August 2016)
Volume 50, Issue 5, Pages (November 2006)
Volume 50, Issue 3, Pages (September 2006)
Volume 55, Issue 6, Pages (June 2009)
In This Issue Cell Volume 158, Issue 5, (August 2014)
Volume 71, Issue 5, Pages (May 2017)
Testicular Cancer Variations in Time and Space in Europe
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Bernard Escudier  European Urology Supplements 
Prognostic Impact of Comorbidity in Patients with Bladder Cancer
Volume 75, Issue 4, Pages (April 2019)
European Urology is “Your” Journal
Economic Burden of Bladder Cancer Across the European Union
Volume 54, Issue 2, Pages (August 2008)
Volume 53, Issue 6, Pages (June 2008)
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 60, Issue 2, Pages 231-238 (August 2011) Long-term Follow-up of Bladder Cancer Patients with Disseminated Tumour Cells in Bone Marrow  Margitta Retz, Jens Rotering, Roman Nawroth, Alexander Buchner, Michael Stöckle, Juergen E. Gschwend, Jan Lehmann  European Urology  Volume 60, Issue 2, Pages 231-238 (August 2011) DOI: 10.1016/j.eururo.2010.12.014 Copyright © 2010 Terms and Conditions

Fig. 1 (a) Progression-free survival, (b) tumour-specific survival, and (c) overall survival depending on cytokeratin-20. PFS=progression-free survival; CK20=cytokeratin-20; TSS=tumour-specific survival; OS=overall survival. European Urology 2011 60, 231-238DOI: (10.1016/j.eururo.2010.12.014) Copyright © 2010 Terms and Conditions

Fig. 2 (a) Progression-free survival, tumour-specific survival, and overall survival stratified by cytokeratin-20 status in bone marrow samples and lymph node involvement. PFS=progression-free survival; CK20=cytokeratin-20; TSS=tumour-specific survival; OS=overall survival. European Urology 2011 60, 231-238DOI: (10.1016/j.eururo.2010.12.014) Copyright © 2010 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.